OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

What Can Residents Learn From an Oncology Fellowship?

November 25th 2021

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss what the benefits are of an oncology fellowship and the takeaways and important lessons Nardello learned from his own breast oncology fellowship at Fox Chase Cancer Center.

Why Should Someone Pursue a Fellowship in Oncology?

November 25th 2021

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss what brought Dr. Nardello to the breast cancer field, what made him decide to pursue an oncology fellowship, and what residents should think about when choosing a fellowship location.

Dr. Shah and Dr. Wang on the Need for Academic and Community Collaboration With CAR T-Cell Therapy

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.

Dr. Shah and Dr. Wang on the Challenges of Managing High-Risk MCL

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the challenges of managing high-risk mantle cell lymphoma.

Dr. Shah and Dr. Wang on Navigating the Referral Process for CAR T-Cell Therapy in Hematologic Malignancies

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss navigating the referral process for CAR T-cell therapy in hematologic malignancies.

Dr. Shah and Dr. Wang on Managing CRS and Neurotoxicity in Leukemia/Lymphoma

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss management strategies for CAR T-cell therapy–related cytokine release syndrome and neurotoxicity in leukemia and lymphoma.

Dr. Shah and Dr. Wang on CAR T-Cell Therapy–Associated Toxicities in Hematologic Malignancies

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the main CAR T-cell therapy–associated toxicities in hematologic malignancies.

Dr. Leal on Developments Made in EGFR Exon 20–Mutant NSCLC Treatment

November 24th 2021

Ticiana Leal, MD, discusses developments made in the treatment of patients with EGFR exon 20 insertion–mutant non–small cell lung cancer.

Dr. Erickson on PARP Inhibitor Maintenance Therapy in BRCA-Mutated Ovarian Cancer

November 24th 2021

Britt Erickson, MD, discusses the benefit of PARP inhibitor maintenance therapy in patients with BRCA-mutated ovarian cancer.

Dr. Saif on Recommendations for Germline Testing in Pancreatic Cancer

November 23rd 2021

Wasif M. Saif, MD, MBBS, discusses recommendations for germline testing in patients with pancreatic cancer.

Dr. Vasan on Future Research Directions for Approved Agents in HER2+ Breast Cancer

November 23rd 2021

Neil Vasan, MD, PhD, discusses future research directions for approved agents used in the treatment of patients with HER2-positive breast cancer.

Dr. Márquez Rodas on the Preliminary Efficacy of BO-112/Pembrolizumab in Advanced Melanoma

November 23rd 2021

Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.

Dr. Reiss Binder on Initial Results of a Phase 1 Study of CT-0508 in HER2+ Solid Tumors

November 23rd 2021

Kim A. Reiss Binder, MD, discusses the initial results of a phase 1 trial, which is evaluating CT-0508 in patients with HER2-overexpressing solid tumors.

Dr. Iqbal on the Emergence of Checkpoint Inhibitors in Upper GI Cancers

November 23rd 2021

Syma Iqbal, MD, discusses the emergence of checkpoint inhibitors in upper gastrointestinal cancers.

Dr. Rosko on Disparities Within Clinical Trials in Multiple Myeloma

November 23rd 2021

Ashley E. Rosko, MD, discusses disparities within clinical trials in multiple myeloma.

Dr. Vaishampayan on the Future Directions for Second-Line Treatment in Urothelial Cancer

November 23rd 2021

Ulka Nitin Vaishampayan, MBBS, discusses future directions for second-line treatment in urothelial cancer.

Dr. Evens on Key Highlights from the RWJ Annual Clinical Practice and Research Summit

November 23rd 2021

Andrew M. Evens, DO, MSc, discusses highlights from the 2021 RWJ Annual Clinical and Practice Research Summit.

Dr. Hinrichs on Unmet Needs with Cellular Therapy in Metastatic Epithelial Cancer

November 23rd 2021

Christian S. Hinrichs, MD, discusses unmet needs with cellular therapies in metastatic epithelial cancer.

Dr. Malhotra on Challenges with Precision Medicine in Advanced Solid Tumors

November 23rd 2021

Jyoti Malhotra, MD, MPH, discusses challenges with precision medicine in advanced solid tumors.

Dr. Bupathi on Considerations for Second-Line Sequencing in RCC

November 23rd 2021

Manojkumar Bupathi, MD, MS, discusses considerations for second-line treatment sequencing in clear cell renal cell carcinoma.